Coronary disease & ACS

Fractional flow reserve- and intravascular ultrasound-guided strategies for intermediate coronary stenosis and low lesion complexity in patients with or without diabetes: a post hoc analysis of the randomised FLAVOUR trial

EuroInterventionPublished prespecified post hoc analysis from the FLAVOUR trial

Authors' conclusion

In patients with intermediate coronary stenosis and low lesion complexity, regardless of diabetic status, FFR guidance had no significant differences in MACE or TVF with a lower frequency of PCI compared with IVUS guidance.

Study context

Population
Patients with intermediate coronary artery stenosis and low lesion complexity, with or without diabetesrandomly assigned patients, 554 (32.9%) had diabetes
Participants
1,682 patients
Comparison
Fractional flow reserve (FFR) vs intravascular ultrasound (IVUS)
Primary endpoint
Major adverse cardiac events (MACE):
  • Death
  • Myocardial infarction
  • Any revascularisation
Follow-up
24 months
Methodological detailsrandomised
  • Randomised

Primary result

As reported in the abstract

Cumulative incidence

9.3% vs 8.3%

P = 0.90

diabetic patients

Cumulative incidence

7.5% vs 8.6%

P = 0.50

non-diabetic patients

Secondary outcomes

OutcomePCI rateP value
PCI rateFFR vs IVUS · diabetic patients; lower with FFR48.2% vs 69.1%P < 0.001
PCI rateFFR vs IVUS · non-diabetic patients; lower with FFR42.6% vs 63.3%P < 0.001

Baseline SYNTAX score

Mean SYNTAX score
8.64±6.03

Target vessel failure (TVF) · 24 months

Cumulative incidence of TVF comparable between FFR and IVUS groups regardless of diabetic status

Original publication

Fractional flow reserve- and intravascular ultrasound-guided strategies for intermediate coronary stenosis and low lesion complexity in patients with or without diabetes: a post hoc analysis of the randomised FLAVOUR trial. EuroIntervention. Published 3 February 2025. doi:10.4244/eij-d-24-00589

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.